ASX CODE: PAR

Paradigm Biopharmaceuticals ASX PAR US investigational new drug

Paradigm submits first investigational new drug application with US FDA

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has set the stage for a speedy entry into the US after filing its first investigational new drug...
Paradigm Biopharmaceuticals ASX PAR Ross River virus phase 2A clinical trial success

Paradigm Biopharmaceuticals’ iPPS reduces Ross River virus joint pain

Paradigm Biopharmaceuticals (ASX: PAR) has reported reduced disease symptoms during a phase 2a trial using its injectable pentosan polysulfate sodium (iPPS) drug on Ross...
Paradigm Biopharmaceuticals ASX PAR pain reduction knee osteoarthritis iPPS

Real world trial of Paradigm Biopharma’s injectable drug reduces osteoarthritic pain by over 50%

A real-world trial using Paradigm Biopharmaceuticals’ (ASX: PAR) injectable pentosan polysulfate (iPPS) treatment has found the drug can provide a reduction in pain of...
Paradigm Biopharmaceuticals ASX PAR bone marrow lesions hip knee cap ankle iPPS

Paradigm Biopharmaceuticals’ iPPS drug reduces bone marrow lesions in hip, knee caps and ankles

As it advances its injectable Pentosan Polysulfate (iPPS) drug towards commercialisation, Paradigm Biopharmaceuticals (ASX: PAR) has noted a clinically meaningful decrease in bone marrow...
Paradigm Biopharma ASX PAR phase 2b secondary endpoints pentosan polysulfate sodium

Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise

Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have...
Paradigm Biopharmaceuticals ASX PAR IND applicaton mucopolysaccharidosis MPS disease

International symposium sets scene for Paradigm Biopharmaceuticals’ MPS trial

Paradigm Biopharmaceuticals (ASX: PAR) has set its sights on applying to the US Food and Drug Administration (FDA) to begin a clinical trial for...
Paradigm Biopharmaceuticals ASX PAR primary endpoints Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals meets primary endpoints in Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals (ASX: PAR) has confirmed the potential of its injectable pentosan polysulfate sodium (iPPS) drug to be “safe and effective” in treating knee...
Paradigm Biopharmaceuticals PAR ASX knee pain reduction osteoarthritis

Paradigm Biopharmaceuticals reasserts osteoarthritis pain reduction results

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has reasserted its previously published figures relating to pain reduction resulting from its flagship drug treatment Pentosan Polysulfate Sodium...
Paradigm Biopharmaceuticals ASX PAR Pentosan Polysulfate Sodium Icahn School of Medicine at Mount Sinai

Paradigm Biopharmaceuticals to deploy iPPS to treat rare joint disease

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) is continuing to expand the gamut of applications for its proprietary Pentosan Polysulfate Sodium (iPPS) drug by signing an agreement...
Paradigm Pharmaceuticals ASX PAR Australian Government research and development tax refund

Australian Government numbs capital expenditure pain for Paradigm Biopharmaceuticals

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has received a further boost in its mission to bring a potentially industry-leading chronic pain medication to the Australian...
Paradigm Biopharma injectable osteoarthritis drug trial reduction chronic pain knee OA

Paradigm’s injectable osteoarthritis drug trial shows major reduction in chronic pain

Australian biotech company Paradigm Pharmaceuticals (ASX: PAR) has reported an average 51.2% reduction in chronic knee pain by a group of osteoarthritis patients being...
Paradigm Biopharmaceuticals ASX PAR Pro Players Elite Network NFL athletes

Paradigm Biopharmaceuticals looks to touchdown its osteoarthritis drug in the United States

Paradigm Biopharmaceuticals (ASX: PAR) has struck a strategic partnership with the Pro Players’ Elite Network (PPEN), a US-based retired professional sporting network comprised of...
Paradigm Biopharmaceuticals ASX PAR chronic pain reduction osteoarthritis

Paradigm Biopharmaceuticals looks to scale summit of chronic pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) continues to make progress on its mission of developing a radical shift in reducing chronic joint pain from osteoarthritis. With...
Paradigm Biopharma ASX PAR complete recruitment Ross River virus clinical study trial

Paradigm Biopharma weathers seasonal change to complete recruitment for Ross River virus study

Paradigm Biopharmaceuticals (ASX: PAR) has completed the recruitment stage of its phase 2a clinical trial in participants with persistent ‘Ross River virus (RRV) induced...
Paradigm Biopharmaceuticals ASX PAR osteoarthritis pain reduction knee Pentosan Polysulfate Sodium

Paradigm Biopharma raises the stakes in osteoarthritis pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has announced further progress in its bid to develop a definitive pain reduction treatment for both elite athletes...
Paradigm Biopharmaceuticals ASX PAR phase 2b clinical trial knee osteoarthritis recruitment

Fast knee pain trial recruitment boosts Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX: PAR) has fully recruited trial participants for its phase 2b clinical trial for knee osteoarthritis, leaving it on track to report...
Paradigm Biopharma ASX PAR pain reduction treatment Pentosan Polysulfate Sodium

Paradigm Biopharma on track to deliver revolutionary pain reduction treatment

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has added more patients to its trail of injectable Pentosan Polysulfate Sodium (PPS), whilst maintaining its 50% pain reduction rate. The...
Paradigm Biopharma ASX PAR osteoarthritis trial recruitment ahead of schedule

Paradigm Biopharma osteoarthritis trial recruitment ‘ahead of schedule’

Paradigm Biopharma (ASX: PAR) has recruited more than 80% of its patients needed for its phase 2b osteoarthritis and concurrent bone marrow lesion clinical...
Paradigm Biopharma ASX PAR AFL Penstosan Polysulfate Sodium osteoarthritis

AFL teams queue up for Paradigm Biopharma’s pain relieving medication

Several doctors from Australian Football League (AFL) clubs are taking advantage of Paradigm Biopharma’s (ASX: PAR) existing drug for the treatment for knee, hip...
Paradigm Biopharma ASX PAR clinical trail ross river virus Pentosan Polysulfate Sodium osteoarthritis

Paradigm Biopharma’s clinical trials in the fast lane

Paradigm Biopharmaceuticals (ASX: PAR) is surpassing its own expectations in recruiting patients for its two phase two clinical trials, which will speed up the...
Paradigm Biopharmaceuticals ASX PAR osteoarthritis pain Pentosan Polysulfate Sodium

Paradigm delivers positive trial results alongside growing patient numbers

Paradigm Biopharmaceuticals (ASX: PAR) has recorded pleasing trial results for its Pentosan Polysulfate Sodium (PPS) drug. In a statement to the market, Paradigm said that...

RECENT POSTS

STOCK SUMMARY

HOT TOPICS

TRENDING POSTS